Tissue Repair Ltd (ASX:TRP)
0.2050
-0.1050 (-33.87%)
Jan 30, 2026, 4:10 PM AEST
Tissue Repair Company Description
Tissue Repair Ltd, a clinical stage biopharmaceutical company, develops advanced wound healing products for chronic wounds and the aftercare of cosmetic procedures in Australia.
The company utilizes Glucoprime technology, an immunogenic active pharmaceutical ingredient that activates macrophages and stimulates immune response for wound healing and skin regeneration.
It develops TR-987, a topical drug in Phase III clinical trial for the treatment of chronic wounds and venous leg ulcers; and TR Pro+, a post-procedure gel for the aftercare of acute wounds, and aesthetic and medical procedures.
Tissue Repair Ltd was incorporated in 2012 and is based in Chatswood, Australia.
Tissue Repair Ltd
| Country | Australia |
| Founded | 2012 |
| Industry | Biotechnology |
| Sector | Healthcare |
| CEO | Tony Charara |
Contact Details
Address: Tower A, The Zenith Chatswood, NSW 2067 Australia | |
| Phone | 61 4 2798 5805 |
| Website | tissuerepair.com.au |
Stock Details
| Ticker Symbol | TRP |
| Exchange | Australian Securities Exchange |
| Fiscal Year | July - June |
| Reporting Currency | AUD |
| ISIN Number | AU0000180887 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Tony Charara | Co-Founder, Chief Executive Officer and Executive Director |
| Dion Cohen | Chief Financial Officer |
| Dr. Darryl Reed | Chief Operating Officer |
| Gary Bird | Chief Commercial Officer |
| Sushma Kejriwal | Company Secretary |